Cathie Wood Increases Stakes in Figma, Arcturus, and 10x Genomics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy TXG?
Source: NASDAQ.COM
- Figma Price Drop: Figma's stock has plummeted 83% from last year's peak, and while analysts predict a significant slowdown in growth over the next two years, its latest quarter showed a 40% year-over-year revenue increase, indicating strong market demand that may attract investor interest.
- Arcturus Financial Status: Arcturus Therapeutics has seen its revenue decline for three consecutive years, with expectations of another 50% cut this year; however, its strong liquidity and the potential of its leading drug candidate led Cathie Wood to increase her stake three times last week, reflecting confidence in its future.
- 10x Genomics Growth Potential: 10x Genomics has experienced a ninefold revenue increase over the past eight years, yet its stock is currently trading at half its IPO price and has yet to achieve profitability; nevertheless, its leading position in single-cell genomic analysis and market demand continue to support its future growth prospects.
- Market Environment Challenges: Despite Cathie Wood typically increasing her holdings during market downturns, last week she only added to her positions in Figma, Arcturus, and 10x Genomics, highlighting the current market challenges for investors, particularly as high-valuation tech stocks face competitive pressures.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TXG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TXG
Wall Street analysts forecast TXG stock price to fall
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 19.810
Low
9.00
Averages
13.00
High
18.00
Current: 19.810
Low
9.00
Averages
13.00
High
18.00
About TXG
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cathie Wood Increases Holdings in Three Stocks Amid Market Volatility
- Circle Internet Group Dynamics: Circle Internet Group's stock plummeted 20% on Tuesday due to concerns over cryptocurrency regulation discussions, yet it reported revenue growth of 53%, 66%, and 77% in its first three quarters; Cathie Wood's decision to buy more shares at this low point reflects her confidence in its long-term potential despite regulatory risks.
- Arcturus Therapeutics Outlook: Arcturus Therapeutics reported a sharp revenue decline for three consecutive years, with projections indicating a further drop to one-fifth of its 2022 revenue by 2026; however, positive clinical trial developments and an extended cash runway to Q2 2028 may provide investor reassurance, prompting Wood to increase her stake, indicating optimism in the biotech sector.
- 10x Genomics Steady Growth: 10x Genomics, a provider of life sciences tools, has seen significant revenue growth in seven of the past eight years, and despite profitability challenges, Wood's continued purchases over four consecutive trading days highlight her belief in its long-term success, particularly with the promising Chromium platform.
- Market Environment Impact: Despite Ark Invest's largest fund declining 11% this year, nearly three times the market's drop, Cathie Wood's strategy of increasing her holdings in these stocks during market volatility suggests a bullish outlook for future rebounds, potentially attracting more investor interest in her investment approach.
See More
Bioptimus Launches Global Initiative for Biological World Model
- Data Generation Initiative: Bioptimus, in partnership with 10x Genomics and Broad Clinical Labs, launches the STELA initiative aimed at profiling up to 100,000 patient specimens, representing a 20-fold increase in scale over existing data, significantly enhancing the data foundation for biomedical research.
- Precision Medicine Advancement: STELA will support M-Optimus by integrating high-resolution spatial transcriptomics and clinical records, enabling researchers to decrypt complex cellular and tissue interactions, thereby accelerating the development of new therapies and predicting patient responses.
- Strategic Industry Collaboration: The partnership between Bioptimus and 10x Genomics combines advanced spatial biology technologies with large-scale AI model development, ensuring that the standardized data generated can support the development of large-scale AI models, driving the application of biomedical data.
- Innovative Quality Control: Collaboration with Broad Clinical Labs will advance the development of next-generation AI-driven quality control metrics, ensuring high data integrity, thus enabling the insights generated by STELA to be effectively translated into clinical diagnostics and precision therapies.
See More
Cathie Wood Quietly Adds to Three Stocks Amid Market Decline
- Figma Price Volatility: Figma's stock has plummeted 83% from last summer's highs, yet its latest quarterly revenue growth accelerated to 40% year-over-year, indicating vulnerability amid shifting market sentiment and competitive pressures in the cloud platform sector.
- Arcturus Therapeutics Investment: Ark Invest has steadily increased its stake in Arcturus Therapeutics over the past week, despite the company's revenue sharply declining over the past three years and expected to be halved again this year, highlighting investor interest in its mRNA technology for rare disease treatments.
- 10x Genomics Growth Struggles: 10x Genomics has seen a ninefold revenue increase over the past eight years, but its stock price has fallen from its IPO price of $38 to the current $18.38, reflecting a lack of profitability and poor future revenue guidance despite strong market demand.
- Market Environment Challenges: With major market indexes declining for four consecutive weeks, Cathie Wood's cautious investment strategy, adding to these three stocks, reflects her confidence in their long-term potential despite facing short-term market pressures.
See More
Cathie Wood Increases Stakes in Figma, Arcturus, and 10x Genomics
- Figma Price Drop: Figma's stock has plummeted 83% from last year's peak, and while analysts predict a significant slowdown in growth over the next two years, its latest quarter showed a 40% year-over-year revenue increase, indicating strong market demand that may attract investor interest.
- Arcturus Financial Status: Arcturus Therapeutics has seen its revenue decline for three consecutive years, with expectations of another 50% cut this year; however, its strong liquidity and the potential of its leading drug candidate led Cathie Wood to increase her stake three times last week, reflecting confidence in its future.
- 10x Genomics Growth Potential: 10x Genomics has experienced a ninefold revenue increase over the past eight years, yet its stock is currently trading at half its IPO price and has yet to achieve profitability; nevertheless, its leading position in single-cell genomic analysis and market demand continue to support its future growth prospects.
- Market Environment Challenges: Despite Cathie Wood typically increasing her holdings during market downturns, last week she only added to her positions in Figma, Arcturus, and 10x Genomics, highlighting the current market challenges for investors, particularly as high-valuation tech stocks face competitive pressures.
See More
PerturbAI Unveils World's Largest CRISPR Atlas for Drug Discovery
- Technological Breakthrough: PerturbAI's release of the 8 million-cell brain atlas represents the world's largest in vivo CRISPR genomic resource, showcasing a significant advancement in measuring gene function and marking a foundational change in biology.
- Collaborative Strength: This dataset was generated in collaboration with NVIDIA, the Allen Institute for Brain Science, and 10x Genomics, providing a framework for systematic evaluation of the brain genome and aiding in the identification of causal mechanisms of disease risk and progression.
- Application Potential: PerturbAI is leveraging its in vivo CRISPR platform and causal AI models to develop best-in-class therapeutics for complex metabolic and chronic diseases, enhancing the scalability and cost-effectiveness of drug discovery.
- Investment Backing: PerturbAI closed an oversubscribed pre-seed funding round in Q3 2025, backed by early-stage investors with deep expertise in AI, biology, and company-building.
See More
PerturbAI Unveils World's Largest In Vivo CRISPR Atlas
- Technological Innovation: PerturbAI's release of the 8 million-cell brain atlas represents the world's largest causal genomics resource, showcasing its ability to measure gene function in living tissue, marking a foundational change in biology that allows for the simulation of therapeutic interventions before costly drug development.
- Collaborative Partnerships: The dataset was generated in collaboration with NVIDIA, the Allen Institute for Brain Science, and 10x Genomics, providing a framework for systematic evaluation of the brain genome and revealing the varying effects of genes across different cell types and biological contexts, thus advancing research in complex metabolic and chronic diseases.
- AI-Driven Drug Discovery: PerturbAI is leveraging its in vivo CRISPR platform and causal AI models to develop best-in-class therapeutics, emphasizing the team's deep expertise in CRISPR, genomics, and machine learning, which enhances the scalability and translatability of therapeutic discovery.
- Investment Background: PerturbAI closed an oversubscribed pre-seed round in Q3 2025, backed by early-stage investors with deep expertise in AI, biology, and company-building, further solidifying its leading position in the biotechnology sector.
See More
Cathie Wood Increases Holdings in Three Stocks Amid Market Volatility
- Circle Internet Group Dynamics: Circle Internet Group's stock plummeted 20% on Tuesday due to concerns over cryptocurrency regulation discussions, yet it reported revenue growth of 53%, 66%, and 77% in its first three quarters; Cathie Wood's decision to buy more shares at this low point reflects her confidence in its long-term potential despite regulatory risks.
- Arcturus Therapeutics Outlook: Arcturus Therapeutics reported a sharp revenue decline for three consecutive years, with projections indicating a further drop to one-fifth of its 2022 revenue by 2026; however, positive clinical trial developments and an extended cash runway to Q2 2028 may provide investor reassurance, prompting Wood to increase her stake, indicating optimism in the biotech sector.
- 10x Genomics Steady Growth: 10x Genomics, a provider of life sciences tools, has seen significant revenue growth in seven of the past eight years, and despite profitability challenges, Wood's continued purchases over four consecutive trading days highlight her belief in its long-term success, particularly with the promising Chromium platform.
- Market Environment Impact: Despite Ark Invest's largest fund declining 11% this year, nearly three times the market's drop, Cathie Wood's strategy of increasing her holdings in these stocks during market volatility suggests a bullish outlook for future rebounds, potentially attracting more investor interest in her investment approach.
See More
Bioptimus Launches Global Initiative for Biological World Model
- Data Generation Initiative: Bioptimus, in partnership with 10x Genomics and Broad Clinical Labs, launches the STELA initiative aimed at profiling up to 100,000 patient specimens, representing a 20-fold increase in scale over existing data, significantly enhancing the data foundation for biomedical research.
- Precision Medicine Advancement: STELA will support M-Optimus by integrating high-resolution spatial transcriptomics and clinical records, enabling researchers to decrypt complex cellular and tissue interactions, thereby accelerating the development of new therapies and predicting patient responses.
- Strategic Industry Collaboration: The partnership between Bioptimus and 10x Genomics combines advanced spatial biology technologies with large-scale AI model development, ensuring that the standardized data generated can support the development of large-scale AI models, driving the application of biomedical data.
- Innovative Quality Control: Collaboration with Broad Clinical Labs will advance the development of next-generation AI-driven quality control metrics, ensuring high data integrity, thus enabling the insights generated by STELA to be effectively translated into clinical diagnostics and precision therapies.
See More
Cathie Wood Quietly Adds to Three Stocks Amid Market Decline
- Figma Price Volatility: Figma's stock has plummeted 83% from last summer's highs, yet its latest quarterly revenue growth accelerated to 40% year-over-year, indicating vulnerability amid shifting market sentiment and competitive pressures in the cloud platform sector.
- Arcturus Therapeutics Investment: Ark Invest has steadily increased its stake in Arcturus Therapeutics over the past week, despite the company's revenue sharply declining over the past three years and expected to be halved again this year, highlighting investor interest in its mRNA technology for rare disease treatments.
- 10x Genomics Growth Struggles: 10x Genomics has seen a ninefold revenue increase over the past eight years, but its stock price has fallen from its IPO price of $38 to the current $18.38, reflecting a lack of profitability and poor future revenue guidance despite strong market demand.
- Market Environment Challenges: With major market indexes declining for four consecutive weeks, Cathie Wood's cautious investment strategy, adding to these three stocks, reflects her confidence in their long-term potential despite facing short-term market pressures.
See More
Cathie Wood Increases Stakes in Figma, Arcturus, and 10x Genomics
- Figma Price Drop: Figma's stock has plummeted 83% from last year's peak, and while analysts predict a significant slowdown in growth over the next two years, its latest quarter showed a 40% year-over-year revenue increase, indicating strong market demand that may attract investor interest.
- Arcturus Financial Status: Arcturus Therapeutics has seen its revenue decline for three consecutive years, with expectations of another 50% cut this year; however, its strong liquidity and the potential of its leading drug candidate led Cathie Wood to increase her stake three times last week, reflecting confidence in its future.
- 10x Genomics Growth Potential: 10x Genomics has experienced a ninefold revenue increase over the past eight years, yet its stock is currently trading at half its IPO price and has yet to achieve profitability; nevertheless, its leading position in single-cell genomic analysis and market demand continue to support its future growth prospects.
- Market Environment Challenges: Despite Cathie Wood typically increasing her holdings during market downturns, last week she only added to her positions in Figma, Arcturus, and 10x Genomics, highlighting the current market challenges for investors, particularly as high-valuation tech stocks face competitive pressures.
See More
PerturbAI Unveils World's Largest CRISPR Atlas for Drug Discovery
- Technological Breakthrough: PerturbAI's release of the 8 million-cell brain atlas represents the world's largest in vivo CRISPR genomic resource, showcasing a significant advancement in measuring gene function and marking a foundational change in biology.
- Collaborative Strength: This dataset was generated in collaboration with NVIDIA, the Allen Institute for Brain Science, and 10x Genomics, providing a framework for systematic evaluation of the brain genome and aiding in the identification of causal mechanisms of disease risk and progression.
- Application Potential: PerturbAI is leveraging its in vivo CRISPR platform and causal AI models to develop best-in-class therapeutics for complex metabolic and chronic diseases, enhancing the scalability and cost-effectiveness of drug discovery.
- Investment Backing: PerturbAI closed an oversubscribed pre-seed funding round in Q3 2025, backed by early-stage investors with deep expertise in AI, biology, and company-building.
See More
PerturbAI Unveils World's Largest In Vivo CRISPR Atlas
- Technological Innovation: PerturbAI's release of the 8 million-cell brain atlas represents the world's largest causal genomics resource, showcasing its ability to measure gene function in living tissue, marking a foundational change in biology that allows for the simulation of therapeutic interventions before costly drug development.
- Collaborative Partnerships: The dataset was generated in collaboration with NVIDIA, the Allen Institute for Brain Science, and 10x Genomics, providing a framework for systematic evaluation of the brain genome and revealing the varying effects of genes across different cell types and biological contexts, thus advancing research in complex metabolic and chronic diseases.
- AI-Driven Drug Discovery: PerturbAI is leveraging its in vivo CRISPR platform and causal AI models to develop best-in-class therapeutics, emphasizing the team's deep expertise in CRISPR, genomics, and machine learning, which enhances the scalability and translatability of therapeutic discovery.
- Investment Background: PerturbAI closed an oversubscribed pre-seed round in Q3 2025, backed by early-stage investors with deep expertise in AI, biology, and company-building, further solidifying its leading position in the biotechnology sector.
See More
